Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Verastem
Biotech
AC Immune CEO bids adieu—Chutes & Ladders
AC Immune CEO bids adieu. Bicara picks up commercial head from Replimune. Infinimmune names CMO to lead clinical push.
Darren Incorvaia
,
Zoey Becker
,
Will Maddox
May 15, 2026 8:30am
AACR: KRAS inhibitors pop in preclinical data debuts
Apr 11, 2024 4:30am
Verastem bags options on GenFleet RAS programs to grow pipeline
Aug 28, 2023 10:30am
Verastem takes on debt to get RAS tumor program to finish line
Mar 28, 2022 8:30am
Verastem CMO quits 2 weeks into the job
Jan 20, 2021 9:50am
Verastem pens KRAS-focused drug licensing deal with Chugai
Jan 8, 2020 9:20am